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Abstract Cancer cells produce galectin-1 as a tumor
promoting protein. Thiodigalactoside (TDG) as a non-
metabolised small drug, is shown to suppress tumor growth
by inhibiting multiple cancer enhancing activities of
galectin-1, including immune cell dysregulation, angio-
genesis and protection against oxidative stress. Thus, using
B16F10 melanoma and 4T1 orthotopic breast cancer
models, intratumoral injection of TDG significantly raised
the levels of tumor-infiltrating CD8? lymphocytes and
reduced CD31? endothelial cell content, reducing tumor
growth. TDG treatment of tumors in Balb/c nude mice
(defective in T cell immunity) reduced angiogenesis and
slowed tumor growth by a third less than in immunocom-
petent mice. Knocking down galectin-1 expression
(G1KD) in both cancer cell types significantly impeded
tumor growth and the sensitivity of the G1KD tumors to
TDG was severely reduced, highlighting a specific role for
galectin-1. Endothelial cells were protected by galectin-1
from oxidative stress-induced apoptosis induced by H2O2,
but TDG inhibited this antioxidant protective effect of
galectin-1 and reduced tube forming activity in angiogenic
assays. We show for the first time that the single agent,
TDG, concurrently prevents many tumor promoting effects
of galectin-1 on angiogenesis, immune dysregulation and
protection against oxidative stress, providing a potent and
novel small molecule as an anti-cancer drug.
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Introduction
Galectin-1 is a b-galactoside binding protein with a highly
conserved carbohydrate-recognition domain (CRD) [1, 2].
A wide range of tumor cells over-express galectin-1, which
has been shown in separate studies to play important roles
in tumor progression, including tumor cell proliferation and
adhesion as well as immune cell inhibition by inducing
apoptosis of activated T cells [3–6]. The outcome of the
immune inhibitory influences is a reduced immune
response by the host, thereby facilitating tumor growth.
Recent reports document that galectin-1 is also important
for tumor angiogenesis [3, 7]. In addition, hypoxia induc-
ible factor-1 (HIF-1), activated during the cellular response
to hypoxia commonly associated with tumor growth
induces galectin-1 expression. Ironically, hypoxia is asso-
ciated with increased levels of oxidative stress, activating
signaling pathways leading to HIF family protein stabil-
ization and activation (reviewed in [8]).
Tumor angiogenesis refers to formation of new blood
vessels induced by tumor-secreted factors and is involved
in tumor progression [9]. Growth of solid tumors strictly
depends on the formation of new blood vessels and this
tumorigenic neovascularization requires several steps
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including stimulation of vascular endothelial cells (ECs)
and destabilization of the basal membrane and extracellular
matrix [10]. Hypoxia, due to poor blood supply, is asso-
ciated with oxidative stress and increased tumor angio-
genesis [11] and is also recognized as a major obstacle to
successful immunotherapeutic outcomes, jeopardizing
cancer therapy. More specifically, the aberrant new blood
vessel formation hampers infiltration and recruitment of
immune effector cells into tumors because of the chaotic
vascular morphology and reduced expression of adhesion
molecules [12]. In fact, it has been shown that normaliza-
tion of the tumor vasculature improved immunotherapeutic
outcomes in a mouse tumor model [13].
High levels of galectin-1 expression have been observed
in growth stimulated ECs as well as in tumor cells, thereby
promoting the proliferation and migration of ECs into the
tumor [5, 7, 14]. In addition, galectin-1 has been linked
with reduction in the migration of lymphocytes, their
trafficking to ECs and transendothelial infiltration into
tumors [15, 16]. Previous studies have shown that by
reducing galectin-1 expression or using a peptide such as
anginex to inhibit CRD binding could inhibit endothelial
function, as well as tumor growth and metastasis [4, 17,
18]. TDG has been more closely examined here as a small
drug inhibitor of galectin-1 that increases the number of
CD8? lymphocytes infiltrating into tumors as well as
suppressing tumor angiogenesis, most likely by preventing
EC survival under conditions of oxidative stress.
Materials and methods
Cell lines and culture conditions
The murine melanoma B16F10 cell line, murine mammary
carcinoma 4T1 cell line and human umbilical vein ECs
(HUVECs) were maintained in DMEM supplemented with
10% heat-inactivated FBS, 50 IU/ml penicillin and strep-
tomycin, 20 mM Hepes buffer, and 1.6 mM L-glutamate
(Sigma). Human EAhy926 ECs were grown in DMEM
containing HAT (hypoxanthine/aminopterin/thymidine) as
previously described [19].
ELISA for detecting galectin-1 binding
96-well plates were pre-coated with mouse laminin
(Invitrogen) in 0.2 M NaHCO3 at 1 lg/well. EAhy926
cells or HUVECs were fixed onto the wells by overnight
incubation in 4% p-formaldehyde/PBS. After washing with
PBS containing 0.05% Tween-20, plates were blocked with
3% BSA/PBS at 37C for 1 h. Recombinant galectin-1
protein (see [20] and Supplemental data for method of
preparation and Supplementary Fig. 1 for purity analysis)
was pre-incubated with serial dilutions of TDG or sucrose
(as a control disaccharide not binding the galectin-1 CRD)
at 37C for 1 h before testing for protein binding to the
plates of laminin or cells. Samples were incubated at RT
for 2 h, then washed before adding biotinylated anti-
galectin-1 IgG. After incubating the plates at RT for 1 h,
the unbound antibody was removed by washing. HRP
streptavidin was added at RT for 1 h before final washing
and addition of Lumigen TMA-6 (GE Healthcare) for
chemiluminescence and photon counting in a plate reader
(FLUOstar Optima; BMG Labtech).
Tube forming assay
Ice-cold MatrigelTM (BD Biosciences) was added at 300 ll
per well to pre-cooled 24-well plates. 50 ll of additional
DMEM containing galectin-1 protein (wild type or P79R
mutant; see Supplemental data for details of preparation
and purity, Supplemental Fig. 1), TDG, or sucrose control
were added to samples as indicated and the plates were
kept at 37C for 30 min. 5 9 105 EAhy926 cells or
HUVECs were plated onto the gel surface in 200 ll of
DMEM. After 18 h of culture, the cell rearrangement and
tube formation were visualized by microscopy. The num-
bers of tubes and the interconnecting nodes were counted
and individual tube lengths recorded.
Generation of galectin-1 knockdown (G1KD) tumor
cell lines
pLKO.1-puro (Sigma–Aldrich) encoding a short hairpin RNA
(shRNA) as an RNAi expressing vector was used with the
targeting sequence for galectin-1: 50-CCTGACCATCAA
GCTGCCAGA-30. The sequence of the non-target control
shRNA was 50-CAACAAGATGAAGAGCACCAA-30. Viral
supernatants were prepared by transient co-transfection of
293T cells (80% confluence) using CaCl2 and 20 lg of
transfer plasmid (pLKO.1-puro, anti-galectin-1 or non-tar-
geting control), 15 lg of packaging plasmid (pCMV-dR8.74)
and 6 lg of envelop plasmid (pMD2.G). Media was replaced
with supplemented DMEM after 8 h. Viral supernatants were
collected after a further 48 h incubation and stored at -80C
until use. 5 ll of the viral stock was added to target cells in
96-well plates in 100 ll of DMEM containing 8 lg/ml of
polybrene. After culturing for 24 h, cells were treated with
puromycin to select for stable transfectants which were cloned
as single colonies and galectin-1 expression analyzed by RT–
PCR and immunoblotting.
Tumor mouse models and TDG treatment
Male C57BL/6, female Balb/c and female Balb/c nu/nu
mice at 5–6 weeks of age were obtained from the Animal
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Resources Centre (Perth, WA, Australia). For all studies,
aged, sex-matched groups of mice were used for the control
and test cohorts. To establish primary solid tumors,
B16F10 or 4T1 cells (7 9 105 cells/mouse in 150 ll of
PBS) were implanted subcutaneously (s.c.) into the left
chest region of C57BL/6 or Balb/c mice. Tumor cells were
incubated with TDG (Carbosynth, UK) at 37C for 1 h
before s.c. injection as tumor challenge. After 3 days, mice
received TDG (40, 80 and 120 mg/kg) by intratumoral
injection which was repeated every 3 days. Tumor volumes
were measured using the following formula: tumor vol-
ume = [longest diameter 9 (shortest diameter)2]/2 or by
volumetric measurement using ultrasound (with an
RMV704 scan head; mean frequency, 25 MHz; resolution,
40 lm; Vevo 770, VisualSonics). After 3 weeks, mice
were sacrificed. All animal experiments were approved by
the Griffith University animal ethics committee, and fol-
lowed the procedures and guidelines set out by the Aus-
tralian NHMRC and ANZCAART regarding animal
welfare.
Cell preparation from excised tissues
Tumors were removed, cut into small pieces and incubated
in DMEM containing 70 U/ml of collagenase (Sigma) at
37C for 1 h before cells were washed and resuspended in
PBS. Tumor infiltrating lymphocytes (TILs) were collected
using Ficoll-Paque Plus (GE Healthcare). Blood was col-
lected by cardiac puncture and peripheral blood mononu-
clear cells (PBMCs) isolated using Ficoll-Paque Plus.
Spleens were removed and treated using 0.83% NH4Cl-Tris
hemolysis buffer. The residual white blood cells were then
analyzed by flow cytometry.
Three-dimensional power Doppler ultrasonography
of tumors
Power Doppler ultrasound imaging of tumors was per-
formed according to a previously published method [19].
Tumor bearing nude mice were anesthetized using isoflu-
rane and the heart rate and body temperature were moni-
tored during imaging by ultrasound. Two-dimensional
images (2-D) were taken at 200 lm intervals and recon-
stituted to produce the final three-dimensional (3-D) vol-
umetric images.
Statistical analysis
All values are expressed as mean ± SE, and the number
(n) of samples used was as indicated. The statistical sig-
nificance of differences between experimental and control
groups was determined by Student’s t test with p-val-
ues \ 0.05 considered significant. Two-way ANOVA with
Bonferroni post-test analysis was performed for tumor
growth experiments. All statistical analyses were per-
formed using GraphPad Prism v4.03.
Results
Intratumoral treatment with TDG as a single agent
suppresses tumor growth by inhibiting galectin-1
Our previous studies had shown that inhibiting galectin-1
using the non-metabolised disaccharide, thiodigalactoside
(TDG), was effective as an adjuvant when added together
with vaccine immunotherapy to promote anti-tumor CD8?
CTL effectors in vivo [21]. In the present study, TDG was
examined as a single agent for its effects on the growth of
the B16F10 melanoma and 4T1 mammary carcinoma as
preclinical models of cancer. TDG, which had no effect on
the growth, adhesion in culture or viability of the cancer
cell lines growing in vitro (ref [21] and Supplemental
Fig. 2A, B) was used to pre-treat the tumor cell burden
before injection in order to block any endogenous galectin-
1 presented by the cells during tumor establishment. The
ensuing treatment then involved intratumoral TDG injec-
tion every 3 days for the duration of the experiments and
was found to significantly reduce tumor growth in a dose-
dependent manner in both cancer models (Fig. 1a–d). On
day 18, the tumor volumes in animals treated with TDG at
120 mg/kg were 3.4-fold less for the melanoma and
2.2-fold less for the mammary carcinomas compared to the
corresponding controls.
Next, intratumoral TDG treatment was examined for its
effect on the progression of tumors derived from the
B16F10 and 4T1 cell lines in which galectin-1 expression
had been knocked down (G1KD) by lentiviral infection
with a galectin-1 specific shRNA-encoding vector. A slight
increase in the levels of galectin-3 expression in the
B16F10 and 4T1 G1KD cell lines was noted compared to
the parental cells (Supplemental Fig. 2C). However, sig-
nificantly reduced levels of the 14.5 kDa galectin-1 protein
expression were obtained using the shRNA galectin-1
knock down vector and individual clones of B16F10 and
4T1 G1KD cell lines were selected (Fig. 1e). These find-
ings were confirmed by quantitative analysis of intracel-
lular levels of protein expression using flow cytometry
whereas the plasmid carrying the non-silencing shRNA
control (NC) showed only a slightly reduced galectin-1
protein expression (Fig. 1f, g). Again, an analysis of adding
TDG, even up to high levels of 20 mg/ml, on the wild type
or G1KD cancer cell lines growing in culture showed no
effects on either proliferation or adhesion over several days
in culture (Supplemental Fig. 2B). The G1KD B16F10 and
4T1 cells were implanted into C57BL/6 or Balb/c mice
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respectively and tumor growth was monitored. The growth
rates of the G1KD tumors were considerably slower than
those of the wild type tumors. Moreover, intratumoral TDG
injection no longer affected the G1KD tumor growth ana-
lyzed by size and weight (Fig. 1h–k). Although no signif-
icant difference was found either by Mann–Whitney rank
sum or students t test between treated and untreated G1KD
tumors, the TDG treated tumors did show a clear trend with
reduced weight suggesting a residual effect of TDG on the
remaining galectin-1 produced by the G1KD tumors. This
data provides support for galectin-1 as the major target for
the effects of TDG on tumor growth.
Sucrose injected in the same manner as for TDG by
intratumoral injection at the equivalent dose had no
detectable effect on the tumor growth (Supplemental
Fig. 3), indicating the effects of TDG were not due to an
osmotic shock. This is also supported by the results in
Supplemental Fig. 2B, because TDG or sucrose, even at
20 mg/ml, had no effect on the growth of the tumor cells in
culture. The results indicating a remarkable and signifi-
cantly reduced growth rate with the Gal-1 knock down
cells were not due to clonal variation. In additional studies,
G1KD pools of cells without clonal isolation as well as a
distinct clone of 4T1 galectin-1 knockdown cells (indicated
as G1KD pool and G1KD-2, respectively, in Supplemental
Fig. 3, right hand panel) were tested by s.c. injection and
tumor volumes were monitored. The results again showed
that both G1KD pools and G1KD-clone 2 growth were also
similarly delayed in growth in agreement with our previous
results in Fig. 1. In addition, a scrambled shRNA trans-
fected 4T1 cell control was tested and showed no signifi-
cant effect on tumor growth.
Fig. 1 TDG suppresses B16F10 and 4T1 tumor growth in vivo.
B16F10 or 4T1 cells were injected s.c. into C57BL/6 or Balb/c mice
respectively. The mice were treated with intratumoral injections of
TDG (40, 80 or 120 mg/kg), every 3 days and tumor volumes
monitored (a B16F10, c 4T1). After 18 days, mice were sacrificed
and tumor weights measured (b B16F10, d 4T1). Galectin-1
expression was knocked down using shRNA. e Levels of galectin-1
expressed in B16F10 and 4T1 cells were analyzed by western blotting
and flow cytometry (f B16F10 and g 4T1). The G1KD B16F10 or 4T1
cells (7 9 105 cells/mouse) were injected s.c. into C57BL/6 or Balb/c
mice respectively, and tumor volumes were monitored (h G1KD
B16F10 and j G1KD 4T1). On day 28, the mice were sacrificed and
the tumor weights were measured (i G1KD B16F10 and k G1KD
4T1). Three independent experiments were performed (total n = 7–9)
and data represent the mean ± S.E. The statistical significance of the
difference between groups compared was determined using students-
t test: *p \ 0.05, **p \ 0.01, ***p \ 0.001
296 Angiogenesis (2011) 14:293–307
123
Intratumoral TDG treatment promotes infiltration
of CD8? lymphocytes into tumors and reduces tumor
angiogenesis in vivo
The effects of intratumoral TDG treatment on resident
immune cell populations was investigated by immunohis-
tochemistry. Of particular note, the levels of CD8? lym-
phocytes in the immunostained sections derived from TDG
treated tumors were markedly increased, with very few, if
any, observed in sections from the untreated B16 or 4T1
tumors (Fig. 2a, b). In addition, numbers of CD8? lym-
phocytes were found to be localised in the extravascular
TDG treated tumor tissue, occurring in regions of tumor
adjacent to the tumor vasculature, indicating increased
tumor infiltration by these lymphocytes.
TDG treatment was found to cause marked changes in
the tumor vessel networks within the treated tumors, par-
ticularly with the B16F10 melanoma where blood vessel
diameters were considerably reduced in treated tumors
(Fig. 2a, b). The average intensity of green fluorescence,
indicating the levels of CD31? as a marker of ECs, was
also greatly reduced in both types of tumors treated with
TDG (Fig. 2c) as was the degree of tumor vascularization
observed in thin sections analyzed by immunohistochem-
istry in both of the treated tumor types (Fig. 2d). Exam-
ining the vasculature in the control tumors showed that
B16F10 melanoma had obvious branched structures of
larger vessel size (Fig. 2d) consistent with a previous
report [22]. By contrast, the 4T1 tumors showed a more
uniform bed of finer capillaries throughout the sections,
with a more web-like appearance (Fig. 2d).
In order to quantify the findings more accurately, the
changes in numbers of tumor infiltrating lymphocytes
(TILs) and EC’s were measured using flow cytometry to
analyse cell populations prepared from whole tumors. In
both tumor types, a significant decrease in the percentages
of cells that were CD31?, as a marker of ECs was detected
(Fig. 2e) and this was associated with significantly
increased levels of CD8? lymphocytes in the TDG-treated
B16F10 and 4T1 tumors (Fig. 2f). Isotype matched control
antibodies showed no detectable background level of
staining (Supplemental Fig. 4).
Previous reports had shown using galectin-1 knockout
mice and anginex as a peptide affecting galectin-1 func-
tion, that host cell/EC derived galectin-1 was important for
tumor angiogenesis [4], although targeting the role of
tumor-derived galectin-1 had not been addressed. When
tumors were established using G1KD cells, the differences
in vascularization observed in thin sections comparing
between control and TDG treated animals was much less
pronounced (Fig. 2d). The significant increase in infiltra-
tion by CD8? lymphocytes observed by immunohisto-
chemistry in the TDG-treated sections from wild type
tumors was not detected in the G1KD tumors (Fig. 2d)
which also showed no significant differences in the CD31?
cell count between the control and TDG-treated tumor
groups (Fig. 2g). In addition, TDG treatment did not sig-
nificantly affect the CD8? lymphocyte count in G1KD
tumors detected by flow cytometric analyses (Fig. 2h).
A comparison of the relative populations of CD4? and
CD8? lymphocytes in TILs, blood and spleen of the ani-
mals treated or not with TDG was undertaken on day 18
(Fig. 3). In addition to the increase in CD8? lymphocyte
numbers, the CD4? lymphocytes among the TIL popula-
tions from the TDG treated B16F10 and 4T1 tumors were
also increased, as was the trend in the CD4? and CD8?
lymphocyte numbers in the blood and spleen, although
differences in the blood and spleen of the control and TDG
treated groups were not statistically significant. These data
suggest that TDG treatment was promoting the infiltration
of CD4? and CD8? T lymphocytes into the tumors as well
as inhibiting tumor angiogenesis.
Relative contribution of T cell immunity and anti-
angiogenic effects of TDG determined by comparing
wild type with immunocompromised mice
The above data indicated that TDG treatment affected
tumor vascularization and increased the CD4? and CD8?
lymphocyte populations of tumors in immunocompetent
wild type mice (Figs. 2, 3). The extent of the specific
contribution from T cell immunity versus the anti-angio-
genic activity provided by blocking galectin-1 with TDG
was examined by comparison with syngeneic Balb/c nude
mice, defective in T cell immunity. Mice with tumors
derived using the parental 4T1 cells were treated with TDG
(120 mg/kg) injected every 3 days and this treatment
suppressed the 4T1 tumor growth rate in nude mice
(Fig. 4a, b), although the effects on both angiogenesis and
tumor growth were not as remarkable as those obtained by
TDG treatment of tumors in wild type Balb/c mice. A
direct comparison of relative tumor growth at day 12 in
treated versus untreated animals showed a 67% reduction
with wild type Balb/c mice versus only a 47% reduction in
the immunocompromised nude mice (Supplemental
Fig. 5). Thus, these results suggest that TDG therapy has
additive effects obtained on both angiogenesis and T cell
immunity by blocking galectin-1.
The percent vascularization obtained by imaging tumor
blood vessels using the ultrasound Power Doppler function
directly showed significant differences in blood flows in
treated tumors associated with considerable inhibition of
tumor angiogenesis, particularly in the more vascularised
peripheral regions of the tumors, as a result of treatment
with TDG (Fig. 4c, e). Similarly, considerably decreased
numbers of CD31? cells existed in the treated tumors
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Fig. 2 TDG regulates tumor angiogenesis and increases CD8?
lymphocyte infiltration into tumors. Frozen solid tumor tissues were
sectioned followed by immunostaining with Alexa Fluor 488 anti-
CD31 IgG (green), PE anti-CD8a IgG (red) and DAPI. a and b Vessel
diameters and c green fluorescence intensity were analyzed (n = 5).
d Wild type (left) or G1KD (right) tumor sections were stained with
anti-CD31 IgG and anti-CD8a IgG. Data shown were representative
of three independent experiments (n = 6–9). Scale bar 100 lm.
Single tumor cell suspensions from tumors were stained with Alexa
Fluor 488 anti-CD31 IgG and PE anti-CD8a IgG and analyzed by
flow cytometry. e CD31? and f CD8? cells in wild type tumors.
g CD31? and h CD8? cells in G1KD tumors. Three independent
experiments were performed (n = 6–9) and percentages were
normalized. The data represent the mean ± S.E. The statistical
significance of the difference between samples compared was
determined by students-t test: *p \ 0.05, **p \ 0.01
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analyzed either by flow cytometry (Fig. 4d) or microscopic
observations of immunostained sections from the TDG-
treated tumors or by examining their average fluorescent
intensity (Fig. 4f, g). Hence, a marked reduction in vas-
cular structures and associated blood flow was observed in
the TDG treated tumors.
TDG inhibits galectin-1 binding via the CRD to laminin
and ECs
We next investigated the mechanisms of action of TDG in
affecting EC function. Given that various types of tumor
cells express and secrete considerable amounts of galec-
tin-1 [23–25], it was important to determine first whether
TDG would block galectin-1 binding to the surface of
ECs. Thus, the ability of TDG to inhibit recombinant
galectin-1 binding to laminin, a major component of
endothelial basal membranes, as well as to the surface of
the human ECs, EAhy926 and HUVECs was determined.
The results showed that TDG dose-dependently inhibited
galectin-1 binding to laminin and to the ECs, whereas
sucrose (as a negative control disaccharide unable to bind
galectin-1), was inactive (Fig. 5a). The inhibitory effects
of TDG on galectin-1 binding to live ECs was also
assessed by flow cytometry (Fig. 5b, c). A mutant form of
galectin-1, P79R, with defective CRD function, was used
as a negative control [26, 27] and exhibited a lack of
binding capacity for laminin as well as low binding to the
ECs compared to the wild type galectin-1 protein
(Fig. 5a–c). Histogram profiles showed high binding lev-
els of galectin-1 to the EAhy926 cells and HUVECs and
that TDG significantly reduced the galectin-1 binding to
these ECs (Fig. 5c). TDG further reduced the low levels
of the mutant P79R binding to cells probably because the
mutant protein retains some residual CRD binding
capacity.
Fig. 3 TDG increases the populations of CD4? and CD8? lympho-
cytes in vivo in tumor-burdened animals. Lymphocytes were prepared
from the tumor tissue, blood and spleen of TDG treated or untreated
mice and were stained with FITC-anti-CD4 IgG and PE-anti-CD8a
IgG. The lymphocytes were gated in SSC-FSC plots and the ratios of
numbers of cells in the CD4? (X-axis) and CD8? (Y-axis) cell
populations were analyzed by flow cytometry. Data are representative
of three independent experiments (n = 6–9)
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TDG suppresses EC function in vitro
Next, the effect of TDG on the biological activities of ECs
was investigated in vitro. Firstly, the ability of ECs to form
tubes was assessed when grown in Matrigel. The number of
tubes and interconnecting tube nodes were found to be
increased by adding recombinant galectin-1 to cultures
(Fig. 6a). However, TDG significantly reduced the number
of tubes and tube nodes formed in the presence of added
galectin-1. In contrast, adding the same levels of the P79R
Fig. 4 TDG suppresses 4T1 growth and decreases tumor angiogen-
esis in nude mice. 4T1 cells were injected s.c. into syngeneic Balb/c
nude mice. a Mice were treated with intratumoral TDG (120 mg/kg)
every 3 days and tumor volumes were monitored. b Comparison of
tumor weights measured at day 13. c Relative vascularization (%) in
each tumor was estimated. d Single cell suspensions from tumors
were stained with Alexa Fluor 488-anti-CD31 IgG and analyzed by
flow cytometry. e 2-D (upper) and 3-D (lower) images of Doppler
signals from intratumoral blood flow on days 6, 9 and 12 (n = 5).
f Frozen tumor tissues were sectioned and stained with Alexa Fluor
488-anti-CD31 IgG (Green) and DAPI and in g levels of green
fluorescence intensity was measured. Scale bar 100 lm. Three
independent experiments were performed (total n = 9–10). The data
represent the mean ± S.E. The statistical significance of the differ-
ence between samples compared was determined by students-t test,
*p \ 0.05, **p \ 0.01, ***p \ 0.001
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mutant galectin-1 protein (with defective CRD) failed to
significantly alter the number of tubes or connected nodes
compared to the controls with no added galectin-1 or
containing sucrose (Fig. 6a). Addition of galectin-1 did not
affect the average tube lengths of HUVECs, but slightly
reduced the lengths of EAhy926 compared to controls and
this reduction was inhibited by TDG (bottom bar graphs in
Fig. 6a). We are unable to explain the reasons for why no
change in HUVEC tube length was detected after adding
Gal-1, despite increased numbers of nodes and tubes. The
P79R mutant protein, albeit less noticeably, also reduced
EAhy926 tube lengths and this reduction in tube length was
prevented by the inclusion of either TDG or sucrose. The
reasons for the unexpected result with EAhy926 cells and
the mutant protein with or without sucrose as negative
controls remains unresolved.
The proliferation of both EAhy926 and HUVEC was
enhanced by the addition of galectin-1 and this enhance-
ment was inhibited by TDG (Fig. 6c). These findings show
that galectin-1 promotes the tube-forming activity of ECs
as well as their proliferation and these processes are
dependent on the CRD binding site of galectin-1 because
they were inhibited by TDG, which has a high affinity for
binding to the galectin-1 CRD.
Inhibiting galectin-1 with TDG affects EC viability
under conditions of oxidative stress
The tumor microenvironment frequently results in regions
with high levels of oxidative stress leading to tumor
necrosis and can also affect EC proliferation and migration,
as well as causing their apoptosis [28]. Hypoxia and
Fig. 5 TDG inhibits galectin-1 binding to laminin and ECs. a TDG
(0.5, 1.0 and 5.0 mg/ml) or sucrose (5 mg/ml) as shown was
incubated with galectin-1 (100 lg/ml). Levels of galectin-1 binding
to laminin or fixed ECs were detected by ELISA. b Purified P79R
galectin-1 mutant protein (100 lg/ml) was applied to laminin coated
plates. Levels of bound wild type or P79R mutant galectin-1 protein
were measured by ELISA. c Live EAhy926 cells and HUVECs were
treated with galectin-1 with or without TDG. After incubation for 1 h,
the cells were fixed and galectin-1 levels binding to ECs were
detected by flow cytometry (dotted line: isotype control). All
procedures were performed at RT. Data represent the mean ± S.E.
and the statistical significance of the difference from the correspond-
ing controls was determined by students-t test: *p \ 0.05,
**p \ 0.01, ***p \ 0.001
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oxidative stress have been shown to promote HIF-1 sta-
bilization and increase galectin-1 secretion by cancer cells
[6]. Therefore the role of galectin-1 and its inhibition by
TDG on EC viability and apoptosis was examined under
conditions of oxidative stress induced by H2O2. EAhy926
cells, with their greater sensitivity to oxidative stress than
HUVECs (Fig. 7a, b) were used for these studies and the
addition of galectin-1 was found to protect against the
cytotoxic effects of 10 lM H2O2 (Fig. 7a). However,
addition of TDG suppressed the antioxidant protection
mediated by galectin-1 on EAhy926 cell survival. Sucrose,
as the control disaccharide, had no effect on the galectin-1
protective activity against H2O2. Next, the annexin V/PI
method was used to measure levels of apoptotic EAhy926
Fig. 6 Galectin-1 increases endothelial function and TDG inhibits
the galectin-1 effects in vitro. a and b Galectin-1 (100 lg/ml), P79R
(100 lg/ml), TDG (1 mg/ml) or sucrose (1 mg/ml) were mixed in
Matrigel. EAhy926 cells or HUVECs were seeded on top of the
Matrigel. After incubation for 18 h, endothelial tube formation was
imaged by microscopy and the number of tubes, connecting tube
nodes and tube lengths were analyzed. Scale bar: 100 lm. c ECs were
incubated with galectin-1 (200 lg/ml) and/or TDG (1 mg/ml). After
incubation for 8 h, cell viability was measured by MTT assay. Data
are representative of three independent experiments (n = 9) with
mean values shown ± S.E. The statistical significance of the
differences was determined by students-t test: * or p \ 0.05, ** or
p \ 0.01, *** or p \ 0.001 (*; versus control, ; versus
respective groups)
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cells when exposed to higher concentrations required to
induce apoptosis (30 lM H2O2). The fraction of early
apoptotic EAhy926 cells (annexin V?/PI-) present after
8–12 h of oxidative stress was markedly reduced when
galectin-1 was included in the cultures (Fig. 7b). TDG was
again found to suppress the protective effect of galectin-1
against the apoptosis induced by H2O2 (Fig. 7c) and the
proportion of apoptotic EAhy926 cells induced by H2O2
was increased when TDG was included compared to the
galectin-1 alone treated group.
The ability of galectin-1 endogenously produced from
tumor cells in culture to protect against H2O2 induced EC
apoptosis was assessed by adding conditioned media pre-
pared from confluent cultures of the cancer cell lines to
EAhy926 cell cultures (Fig. 7d). When conditioned media
from the wild type B16F10 or 4T1 cell lines was added to a
final concentration in the EC media of 30%, the levels of
H2O2 induced EC apoptosis over 12 h incubation detected
by FITC annexin-V? staining was reduced from 24.55 to
17.25% and 21.55% respectively (p \ 0.05). However,
Fig. 7 Galectin-1 promotes EC survival against oxidative stress and
TDG inhibits the antioxidant galectin-1 protective effect. EAhy926
cells treated with galectin-1 (200 lg/ml), TDG (1 mg/ml) and/or
H2O2 (10 lM) as indicated were incubated for 2, 4 or 8 h. a Cell
viability was measured by MTT assay. b and c Cells were stained
with FITC-annexin V and PI, and analyzed by flow cytometry
(X-axis; FITC-annexin V, Y-axis; PI). b Early apoptotic cells
(annexin V?/PI-) in samples as a percent of the total cell number
are presented in the bar graph. c Representative scatter plots from
flow cytometric analyses. Two independent experiments (n = 6) were
performed to obtain the data in b shown as the mean ± S.E. The
statistical significance of the differences between groups compared
were determined using students-t test: *p \ 0.05, **p \ 0.01 or 
p \ 0.05. d EAhy926 cells treated with conditioned media (CM)
derived from confluent B16F10 or 4T1 tumor cell cultures, either wild
type (WD) or G1KD as indicated. The conditioned media was added
at 30% final concentration to the ECs and incubated for 12 h with or
without TDG (1 mg/ml) and 10 mM H2O2 as shown. Cells were then
stained with FITC-annexin V plus propidium iodide (PI), and
analyzed by flow cytometry. Each scatter plot shows the average
value for the gated annexin V? cell population as % of total ± S.E.
(n = 2)
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30% conditioned media from the B16F10 or 4T1 G1KD
cell lines was not as protective and H2O2 induced EC
apoptosis was increased to 30.8% with the 4T1 G1KD
media (p \ 0.05). When the added 30% conditioned media
also included TDG (1 mg/ml), this had little difference
with the G1KD conditioned media but negated the pro-
tective effects of the conditioned media from the galectin-1
wild type cancer cells and the levels of H2O2 induced EC
apoptosis were similar to the controls (Fig. 7d). These
results are consistent with a protective effect provided by
secreted galectin-1 from the tumor cells against oxidative
stress.
Hence, galectin-1, which has been shown by us
(Fig. 1e–g and ref [21]) and others [25, 29, 30] to be
commonly expressed and secreted by tumor cells will act to
protect ECs and promote their function in tumor tissues,
particularly in regions of high oxidative stress known to be
common in tumors [11]. However, TDG, is a suitable agent
for blocking the protective functions of galectin-1 on ECs.
Discussion
Galectins bind b-galactosides such as lactose, lactulose and
N-acetyllactosamine (Galb1,3/4GlcNAc) ‘‘LacNAc’’ with
low inhibitory potency and Kd values of *1.0 and
*0.2 mM, respectively whereas natural disaccharides that
are extended from the C30 position of galactose, replacing
the 30-OH, showed enhanced affinity for some galectins
[31]. Compared to the natural ligands such as those above,
TDG (which we have used extensively here and elsewhere
[1]), has advantages because it is readily available, has a
higher affinity and Jd of *78 lM for galectin-1 and is a
simple, synthetic and non-metabolizable disaccharide.
TDG was very effective at suppressing tumor growth by
inhibiting multiple tumor promoting and protective activ-
ities of tumor-derived galectin-1, including immune cell
dysregulation, angiogenesis, and protection against oxida-
tive stress. Indeed, intratumoral treatment with TDG sig-
nificantly suppressed both melanoma and mammary
carcinoma growth in mouse models, with much less effect
observed for the G1KD tumors in which the protective
functions of tumor-derived galectin-1 would be greatly
reduced (Fig. 1). Therefore, our evidence strongly impli-
cates TDG acting mainly by blocking the CRD of galectin-
1 to exert its effects and interfere with the tumor-promoting
and protective functions of the tumor-derived galectin-1
protein. Although a contribution of other galectins such as
galectin-3 remains a possibility, our evidence, particularly
based on the galectin-1 knockdown tumor studies, supports
a key role for tumor derived galectin-1 in tumor develop-
ment and makes the contributions of other members of the
galectin family much less likely [32].
Perhaps most interestingly, one of the significant effects
demonstrated here with intratumoral TDG treatment was
the large increase in numbers of tumor-infiltrating CD4?
and CD8? lymphocytes (Figs. 2, 3). Similarly, the popu-
lations of CD4? and CD8? lymphocytes in blood and
spleen as immune organs were also increased following
this treatment (Fig. 3).
We attempted to resolve the relative contribution med-
iated by the increased infiltration of the immune effector T
cell populations versus the anti-angiogenic activity and
which is the most important outcome that results from
TDG inhibition of galectin-1 function. Thus, the compari-
son revealed that intratumoral TDG treatment suppressed
tumor volume in nude mice by 47% versus the untreated
control (Fig. 4), which was much less than the 67%
reduction obtained when TDG was used to treat tumors in
immunocompetent mice. These differences highlight the
importance of T cell immunity and tumor infiltration by
TILs to maximize the combined effects of TDG-mediated
inhibition of galectin-1 function on both angiogenesis and
immune activation. Supporting this viewpoint, our previous
results [21] showed that TDG treatment promoted the
induction of splenic-derived CD8? CTL responses raised
against breast cancer cells and slowed tumor progression.
Hence, blocking galectin-1 induces greater anti-tumor
effects by a combination of effects of modulating tumor
neovascularization and promoting the infiltration of CD8?
T cells into the tumors.
The inhibitory effects of TDG on the pro-angiogenic
function of galectin-1 were shown to be highly significant,
both in vitro and in vivo, reducing binding to laminin and
the tube-forming activity of ECs, as well as EC prolifera-
tion (Fig. 6). More importantly, our data provides a pos-
sible explanation for how TDG could act to inhibit the
tumor protective function of galectin-1 in promoting sur-
vival of ECs subjected to tumor derived oxidative stress,
with the result that TDG blocking galectin-1 would mean
greater exposure to the tumor oxidative stress, enhancing
the loss of EC by apoptosis (Fig. 7). This could explain the
marked changes observed in the tumor vascular networks
and the CD31? EC populations within tumors, which were
considerably reduced by intratumoral TDG treatment
(Figs. 1, 2). In addition, we have for the first time shown
considerable reductions in blood flow occurring within the
TDG treated tumors, particularly in the highly vascularised
periphery. These observations confirmed that TDG, as a
single agent, inhibited tumor angiogenesis by blocking the
functions of galectin-1 in promoting EC growth and sur-
vival and blood flow in our tumor models and presumably
would do so in other tumors.
Anti-angiogenic therapy and immunotherapy are cur-
rently being used to improve the treatment of cancer
patients. Enhancing immune responses by using cancer
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vaccines or adoptive transfer of ex vivo expanded immune
cells has significantly progressed recently and several
strategies are already being tested. Although tumor-specific
T cells in the circulation can be effectively generated using
these protocols, they have met with limited success with
complete responses being uncommon [33]. Our results
highlight that inhibiting galectin-1 function with TDG has
multiple effects including promoting increased numbers of
immune cells and their infiltration into tumors, apparently
involving modifications to the tumor vasculature. Accu-
mulating evidence suggests that the lack of correlation
between the presence of circulating immunotherapy-
induced lymphocytes and tumor regression is probably due
to the restricted lymphocyte infiltration and recruitment
caused by physical barriers associated with biologically
aberrant tumor neovasculature [12, 34]. In order to evade
immune cell infiltration, tumors decrease EC expression of
adhesion molecules, such as ICAM-1, VCAM-1 and
E-selectins, thereby preventing lymphocytes from traf-
ficking into tumors [35, 36]. It has been shown that nor-
malization of the aberrant tumor vasculature can increase
tumor infiltration of cytotoxic T cells leading to enhanced
survival of experimental animals [13]. In addition,
administration of anti-vascular endothelial growth factor
(VEGF) antibody to disrupt the VEGF/VEGFR-2 signaling
axis increases the effects of adoptive T cell transfer therapy
in the B16 murine melanoma model by normalizing the
vasculature to allow T cell extravasation into the tumor
stroma [37]. Therefore, for tumor immunotherapeutic
strategies to be more effective, it may be beneficial to
normalize their abnormal tumor blood vessels, perhaps
using a drug such as anti-VEGF or TDG.
Galectin-1 is becoming widely recognized as an
important lectin protein with significant roles in tumor
progression and one of the roles of galectin-1 is its con-
tribution to tumor cell evasion of immune cell surveillance
[38, 39]. Galectin-1 has been shown to directly suppress T
cell immunity by inducing T cell apoptosis [38], inhibiting
T cell activation [40] and promoting regulatory T cell
function [41]. In addition, we previously showed that
blocking galectin-1 with TDG increased the induction of
tumor-specific CD8? T cell cytotoxicity, thereby sup-
pressing growth of breast tumors in a murine model [21].
Therefore, blocking galectin-1 with metabolically stable
disaccharides such as TDG should protect T cells from the
negative impact of tumor derived galectin-1, and enhance
T cell activity against many different types of cancers.
Another reason why galectin-1 is a promising new
cancer target is because of its angiogenic promoting
activities and its highly increased expression by tumors and
tumor endothelium where elevated galectin-1 promotes EC
proliferation and migration [7, 30]. Adding to this area, our
results from the tube-forming assay using Matrigel and the
MTT assay further advance understanding of the mecha-
nisms whereby exogenous galectin-1 promotes angiogen-
esis by enhancing the tube-forming activity of ECs and
their cell proliferation as observed with both EAhy926 and
HUVECs (Fig. 6). These studies suggest that galectin-1 has
an important function in cell to cell adhesion of ECs that is
mediated by the CRD. Consistent with these reports and
our results it appears that galectin-1 produced by tumors
directly contributes to the formation of abnormal tumor
vascular endothelium typifying the blood vessels in solid
tumors as another of its tumor promoting functions. Thus,
it was shown recently that tumor-derived and secreted
galectin-1 is transported inside ECs where it specifically
promotes H-Ras signaling, activating the Raf/mitogen-
activated protein kinase/extracellular signal-regulated
kinase (Erk) kinase (MEK)/Erk pathway to promote EC
proliferation [14].
Hypoxia and oxidative stress are other important fea-
tures of tumor microenvironments [11], where galectin-1
also plays a role as a well described hypoxia-inducible
protein, mediated by the HIF-1 transcription factor [6, 29].
A poor blood supply due to the abnormal outgrowth of
chaotically arranged blood vessels frequently results in
regions of oxygen insufficiency within tumors. This pro-
motes production of reactive oxygen species (ROS) [11]
causing HIF-1 stabilization which in turn induces tran-
scription of VEGF, the glucose transporter-1 (GLUT-1)
and galectin-1 [6]. On the basis of our results, it is now
clear that galectin-1 secretion by tumor cells will protect
EC survival and promote their growth, reducing the levels
of apoptosis caused by tumor-associated oxidative stress.
Blocking the CRD of galectin-1 with TDG suppressed its
protective effects against hydrogen peroxide-induced oxi-
dative stress to ECs, and would promote vascular EC
function within the tumor microenvironment. Given that
the galectin-1 molecule contains six cysteine residues and
is secreted from cells in the reduced form, perhaps galec-
tin-1 could act as an antioxidant by conversion of its cys-
teines to sulfenic or sulfonic acids thereby absorbing ROS
produced by tumors under oxidative stress [20, 42]. Cer-
tainly, our results showed that blocking the CRD of
galectin-1 suppressed its protective effects against hydro-
gen peroxide-induced oxidative stress to ECs. However,
the precise contributions of galectin-1 to the pro-angio-
genic activities within tumor regions undergoing oxidative
stress, including the relationship between the structures of
reduced versus oxidized galectin-1 and biological actions
of the galectin-1 CRD remain to be resolved.
Intensive chemical structural studies have been aimed at
developing more effective and selective galectin inhibitors
or their conjugates. Such compounds may produce stronger
anti-tumor effects than the TDG disaccharide used here as
proof-of-principle. For example, Nilsson et al. [43, 44]
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have developed TDG derivatives bearing aromatic amide
substituents and aromatic lactose 2-O-ester derivatives
with much lower Kd values than the prototypic disaccha-
ride used in our study. In addition, a b-sheet forming
peptide-based galectin-1 antagonist has been shown to
significantly suppress tumor angiogenesis [4, 45, 46].
Whether these compounds will prove to be effective and
free of side effects in vivo remains to be demonstrated.
To conclude, our results emphasize the substantial
promise of drugs such as TDG as inhibitors of galectin-1,
an emerging target against cancer. Since galectin-1 is a
multi-functional protein promoting tumor progression,
such inhibitors should now be tested in clinical trials. In
addition, the discovery that blocking galectin-1 function
promotes T-cell infiltration into tumors supports the ther-
apeutic potential for combining galectin-1 inhibitors as
adjuvants to be used with immunotherapy and/or chemo-
therapy to improve existing cancer treatments.
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